ADX-626 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,395 results for “ADX-626”

Trials

View all 3426 →

Phase 1 Study of ADX-626 in Healthy Participants

44 participants · First posted Jul 23, 2025

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

198 participants · First posted Sep 22, 2025

Evaluation of 626 in Healthy Adult Subjects

50 participants · First posted Nov 5, 2024

Drugs

View all 1222 →

MIB-626

A-626

MV-626

Organizations

View all 25 →

Agensys, Inc.

United States

Hungarian Academy of Sciences

Hungary

Orano Med LLC

United States

News

View all 722 →

ADARx Raises $446M in Upsized Nasdaq IPO, Adds AbbVie Investment for siRNA Pipeline

Q32 Bio Delays Phase 2 Trial of ADX-097 in ANCA-Associated Vasculitis

ADARx Pharmaceuticals Initiates Phase 3 Trial for ADX-324 in Hereditary Angioedema, Receives FDA Orphan Drug Designation

Page 1 of 540